This study enrolls people with TRK fusion cancer. The purpose of this study is to learn more about the effectiveness of the drug VITRAKVI (generic name: larotrectinib) for TRK fusion cancer that has spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. Read More
Patients with TRK fusion cancer (locally advanced or metastatic solid tumor harboring an NTRK gene fusion).
Your physician has decided to treat you with larotrectinib.
This study enrolls adults with esophageal cancer. The purpose of this study is to compare the effects of different combinations of medications to treat this cancer. Atezolizumab and tiragolumab are experimental drugs, which means the U.S. Food and Drug Administration (FDA) has not approved them, alone or in combination, for the treatment of esophageal cancer. Read More
Adults ages 18+.
Diagnosed with esophageal cancer (squamous cell carcinoma of the esophagus) in stage II-IIVA.
The cancer is unresectable, which means you are unable to unwilling to have surgery.
You have received chemoradiotherapy and your disease did not worsen.
This study enrolls adults who have been diagnosed with borderline personality disorder. This study is being done to see if the study drug called, BI 1358894, may help people with BPD in the future. Read More
Adults ages 18-65 years.
Diagnosed with Borderline Personality Disorder.
This study enrolls people with Multiple Sclerosis who have already enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC). The purpose of this study is to learn more about the experiences of people with MS who are having a natalizumab infusion. Read More
Adults ages 18+.
Have multiple sclerosis.
Are enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC),
Have taken natalizumab for the treatment of MS for at least six months.
This study enrolls adults from the emergency department and the community who have a confirmed COVID-19 infection and can provide the results of their positive PCR testing for COVID. The purpose of this research study is to help us control the spread of COVID-19 by having accessible means of testing for the disease. If successful, this would allow individuals to determine if they have COVID-19 without leaving their home, which may limit the spread of the disease. We expect that you will be in this study for 1 day. A home collection kit will be brought to your home by a courier. You will be asked to use the home kit to prick your finger and place several drops of blood in a collection tube that we will have analyzed using the new test that we are studying. Once you have collected your blood you will place it in a mailing envelope with a prepaid label that we will provide and call delivery service. The delivery service will pick up your sample from your home and deliver it to us. You will also need to answer a few questions about your symptoms and your demographics with us by phone and provide a copy of your PCR COVID-19 test results. This study takes place in Buffalo, NY Read More
- Adults ages 18+
- Symptoms present for 25 days or less
- Patients who are confirmed positive for COVID-19 via PCR test.
- This study is not open for open enrollment: You may be invited to participate if you meet other eligibility criteria.
This study enrolls adults who have had heart failure or heart attack or who are generally healthy. The purpose of this study is to learn more about how these types of cardiovascular issues happen at a biological level. We will do that by looking at the immune cells in the blood. Read More
Adults ages 18+
Generally healthy OR are presenting to the hospital with heart failure or acute myocardial infarction (heart attack).